• 대한예방의학회:학술대회논문집
• /
• 1998.10b
• /
• pp.125-126
• /
• 1998

• Clinical and Experimental Vaccine Research
• /
• v.12 no.4
• /
• pp.298-303
• /
• 2023

Purpose: This qualitative study utilizing phenomenological methodology aimed to depict parental measles mumps rubella (MMR) vaccine acceptance through the work experiences of health personnel. Materials and Methods: Twenty-two public health workers working as vaccination providers in the three southern border provinces of Thailand were recruited. In-depth, face-to-face, semi-structured interviews were conducted. Data were analyzed using thematic analysis. Results: Four main themes emerged: (1) religious beliefs, (2) personal disagreements, (3) fear and mistrust regarding potential vaccine side effects, and (4) misperceptions about the potential severity of measles. Four subthemes were identified: (1) haram (prohibited), (2) the will of Allah, (3) spousal disagreement, and (4) disagreement from a religious leader. The results of this study indicated that perceived religious prohibition was the most important reason for refusing to vaccinate among Muslim parents. Vaccine-hesitant parents were concerned that the vaccine might contain gelatin derived from pig products. Also, halal certification of the vaccine was required from Muslim parents to ensure that vaccine has been approved for Muslims. Meanwhile, a lack of knowledge and positive attitudes concerning immunizations of vaccine-hesitant parents were also found as predominant reasons for incomplete childhood immunizations in the deep south of Thailand. Conclusion: Health education and engagement by religious leaders to endorse the vaccination and bridge the gap between religious beliefs and vaccine acceptance is needed to overcome this issue. This study findings could be effectively applied to improve vaccination uptake in a Muslim majority context.

• Journal of Preventive Medicine and Public Health
• /
• v.18 no.1
• /
• pp.137-147
• /
• 1985

To assess the childhood immunization level of urban and rural areas, 250 mothers of $6{\sim}23$ months old children residing in Namsan 1 Dong, Taegu, and 264 mothers of the same age children residing in five areas of Kyungsan Gun where community health practitioners are assigned were interviewed in March, 1984. Immunization rate for BCG was 98.0% in urban area and 95.8% in rural area. Among children who had BCG vaccination 91.4% of them were immunized within 1 month after birth in urban area and 88.1% in rural area. The percentage of children who received three doses of DPT vaccine was 83.2% in urban, and 87.5% in rural area ana that for the polio vaccine was 80.8% in urban and 87.9% in rural area. Only a few children have never been immunized with either BCG or DPT or polio vaccine. Overall immunization rate for measles was 64.4% in urban area while it was 55.3% in rural area and that for mumps and rubella was 50.4% in urban area as compared with 36.0% in rural area. However, among children of 15 months old and above the percentage of measles vaccination was 85.3% in urban area and 73.7% in rural area. Mumps and rubella vaccination rate was 77.6% in urban area and 62.4% in rural area. These differences in measles, mumps and rubella vaccination rates between urban and rural areas were statistically significant (p<0.05). Such findings as improved immunization level, no significant differences in BCG, DPT and polio vaccination rate between urban and rural areas, and fewer mothers in rural area have not vaccinated their children than mothers in urban area because of their ignorance may be attributed to the general improvement of living standard and implementation of the maternal and child health services of the government. Nevertheless many of the mothers in rural as well as urban area have not immunized their children on time and measles, mumps and rubella vaccination rates are substantially lower than other childhood immunizations. Future immunization activity should be geared to reinforcing these areas.

• Clinical and Experimental Pediatrics
• /
• v.48 no.9
• /
• pp.960-968
• /
• 2005

Purpose : This multi-center, open-label, clinical study was designed to evaluate the safety and immunogenicity of a trivalent, live, attenuated measles-mumps-rubella(MMR) vaccine, $Priorix^{TM}$ in Korean children. Methods : From July 2002 to February 2003, a total of 252 children, aged 12-15 months or 4-6 years, received $Priorix^{TM}$ at four centers : Han-il General Hospital, Kyunghee University Hospital, St. Paul's Hospital at the Catholic Medical College in Seoul, and Korea University Hospital in Ansan, Korea. Only subjects who fully met protocol requirements were included in the final analysis. The occurrence of local and systemic adverse events after vaccination was evaluated from diary cards and physical examination for 42 days after vaccination. Serum antibody levels were measured prior to and 42 days post-vaccination using IgG ELISA assays at GlaxoSmithKline Biologicals (GSK) in Belgium. Results : Of the 252 enrolled subjects, a total of 199 were included in the safety analysis, including 103 from the 12-15 month age group and 96 from the 4-6 year age group. The occurrence of local reactions related to the study drug was 10.1 percent, and the occurrence of systemic reactions was 6.5 percent. There were no episodes of aseptic meningitis or febrile convulsions, nor any other serious adverse reaction. In immunogenicity analysis, the seroconversion rate of previously seronegative subjects was 99 percent for measles, 93 percent for mumps and 100 percent for rubella. Both age groups showed similar seroconversion rates. The geometric mean titers achieved, 42 days pos-tvaccination, were : For measles, in the age group 12-15 months, 3,838.6 mIU/mL [3,304.47, 4,458.91]; in the age group 4-6 years, 1,886.2 mIU/mL [825.83, 4,308.26]. For mumps, in the age group 12-15 months, 956.3 U/mL [821.81, 1,112.71]; in the age group 4-6 years, 2,473.8 U/mL [1,518.94, 4,028.92]. For rubella, in the age group 12-15 months, 94.5 IU/mL [79.56, 112.28]; in the age group 4-6 years, 168.9 IU/mL [108.96, 261.90]. Conclusion : When Korean children in the age groups of 12-15 months or 4-6 years were vaccinated with GlaxoSmithKline Biologicals' live attenuated MMR vaccine ($Priorix^{TM}$), adverse events were limited to those generally expected with any live vaccine. $Priorix^{TM}$ demonstrated excellent immunogenicity in this population.

• Proceedings of the Computational Structural Engineering Institute Conference
• /
• 2004.10a
• /
• pp.387-394
• /
• 2004

In the structural analysis procedure using finite element technique, the performance of a linear equation solver is critical because the linear equation solving part spends most of the computing time for finite element analysis codes. However, most of researchers are still using inefficient profile-based direct solvers such as the band solver or the skyline solver. In this research, we introduce the multifrontal solution method as an efficient direct solution method for structural analysis, and show the efficiency and performance of the multifrontal solution method by comparing the performance of our own implementation of the multifrontal method with the band solver or the skyline solver. In addition, we also compare the performance of our solver with other implementations of the multifrontal method such as WSMP and MUMPS as well as commercial structural analysis packages such as ABAQUS and NASTRAN. Through the performance test results, the usefulness and efficiency of our domain-wise multifrontal solver for structural analysis is shown.

• Clinical and Experimental Pediatrics
• /
• v.49 no.3
• /
• pp.229-234
• /
• 2006

Varicella, which is mostly a benign disease, but also can cause considerable health burden in the community, can be prevented by immunization with live attenuated varicella vaccine. Higher uptake of varicella vaccine by universal immunization in North America has apparently been associated with decline in the number of reported cases of varicella, varicella-related hospitalizations, and the number of deaths caused by complications of varicella. On the contrary, there has been some reluctance in endorsing varicella vaccine for universal immunization in most of European countries. Concerns include unanticipated outbreaks of varicella among vaccine recipients, risk of varicella among unvaccinated adults, risk of herpes zoster among vaccinees as well as unvaccinees. Recently developed measles, mumps, rubella, and varicella combination vaccine and herpes zoster vaccine that may be licensed in the upcoming years may be the solution for varicella vaccine to be utilized in a greater scale. In Korea several varicella vaccine products have been utilized since late 1980. The adoption of varicella vaccine for universal immunization since 2005 along with the changing view in varicella prevention strategy mandates more studies for immunogenecity and efficacy of varicella vaccines as well as more surveillance to delineate the changes in epidemiology of varicella in Korea.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1996.11a
• /
• pp.115-120
• /
• 1996

Vaccination has been considered to be the most effective way to control infectious diseases. Currently, many vaccines used in humans are live-attenuated or killed microorganisms. Polio, mumps, and measles vaccines are live-attenuated. Killed vaccines include cholera and pertussis vaccines, These conventional vaccines, however, suffer from some problems. In the case of live-attenuated vaccines, reversion to virulence is observed in a small but significant number of clinical cases each year. In killed vaccines, due to the possible hazard to employees working with live pathogens, the cost of preparation is high. Killed vaccines also need to be given in multiple doses, Furthermore, both live-attenuated and killed vaccines have possible presence of cellular materials leading to side effects. Moreover, there are diseases such as malaria and hepatitis for which conventional attenuated and killed vaccines are not available because the pathogens cannot be grown in sufficient amounts to allow the classical methods to be used.

• Pediatric Infection and Vaccine
• /
• v.7 no.1
• /
• pp.83-93
• /
• 2000

Purpose : Urabe AM-9 strain was known to be associated with increased aseptic meningitis. The reason for high incidence of vaccine-associated meningitis was known that nucleotide(nt) substituted form G to A at position 1081 of the hemagglutinin-neuraminidase(HN) gene and therefore, glutamic acid changed to lysine at amino acid 335. We assessed by comparing nt sequence of the HN gene form Urabe AM-9 strain with wild strain and documented the correlation between nt substitution and vaccine-associated meningitis. Methods : Two lots of Urabe AM-9 vaccine distributed in Korea and mumps wild strains isolated from 1998 through 1999 were analysed. Analysis was made by nt sequencing following amplification of HN gene by RT-PCR. Results : Nucleotide substitution at position 343, 1476, 1570 was not found in both Urabe AM-9 vaccines and wild strains. But analysis of vaccine strains and wild strains isolated from patients revealed substitution from G to A at nt 1081 of the HN gene. Therefore, it encodes lysine instead of glutamic acid at amino acid 335. There was no mixture from of G and A at nt 1081. Nt at 1470 of one lot of Urabe AM-9 vaccines changed from C to A after Vero cell passage. Nt at 1727 of vaccines and wild strains was substituted A to G, so it encodes glycine instead of aspartic acid. Conclusion : Nucleotide analysis of HN gene revealed that nt 1081 of Urabe AM-9 vaccines and wild strains had wild type AAA($Lys^{335}$) instead of variant type GAA($Glu^{335}$). The results of this study suggest that there was a probability of vaccine-associated meningitis due to Urabe AM-9 in Korea before. But incidence of actual side effect was not evaluated because there was no reporting system in Korea.

• Pediatric Infection and Vaccine
• /
• v.7 no.2
• /
• pp.183-192
• /
• 2000

Purpose : Adverse events(AE) associated with vaccination have not been systematically monitored in Korea. But since 1994, several deaths after inactivated mouse brain derived Japanese encephalitis vaccine injection arouse the safety problem of immunization in the public, and a evaluation of vaccination program including the effectiveness and safety problem had been started. We have been using MMR vaccine containing Japanese mumps vaccine strains, which are known to be associated with the high rate of adverse events including aseptic meningitis, for the last decade. Methods : We conducted a prospective study of vaccine adverse events associated with MMR vaccine through a tracking system using telephone calls. We followed up 7,594 cases of MMR vaccinees. Results : Reported adverse events included fever, couvulsion, parotitis, and aseptic meningitis. Nine cases of parotitis and seven cases of aseptic meningitis were recognized during follow up period. The incidence of both parotitis and aeptic meningitis was $85.1/10^5$, for Urabe mumps strain. For Hoshino strain, the incidence of parotitis and aseptic meningitis was $158.0/10^5$ and $94.8/10^5$, respectively. Conclusions : The incidence of adverse events was to be a higher than that of natural infection in Korea and was comparable to the results of studies done in other countries.

• The Microorganisms and Industry
• /
• v.10 no.1
• /
• pp.2-6
• /
• 1978

백신이란 학문의 원조는 고금 동서를 불문하고 영국의 Jenner라는 것은 우리가 잘아는 사실이다. 이것은 약 200년전의 일이며 그후 각종 전염병예방 백신이 개발되어 오늘날 우리인간은 예전ㅇ 비해 각종 전염병에 대해 큰 은혜를 받고 있는 셈이다.특히 1949년 미국의 Enders박사 일맥의 조직 배양의 개량법에 의한 바이러스의 대량 배양과 정제및 농축이 용이하게 된것은 백신생산 개발문제뿐만아니라 바이러스학과 전염병 예방학의 발전의 일대혁신을 가져왔으며 세균학에 있어서 Koch의 고형배제를 사용하여 많은 병원성세균의 발견을 하게된 것과 비슷한 느낌을 준다. Enders의 조직배양의 modern technique는 아직까지 원인불명인 여러 종류의 바이러스 전염병 병원체가 구명되었으며 지금도 계속 새로운 바이러스가 발견되고 있는 중이다. 그 대표적인 예를 들면 폴리오(Polio)를 중심으로 Coxsackie virus의 A및 B군과 ECHO virus등 장관계바이러스들의 발견과 그 체계적정비 그리고 Adeno virus를 위시한 호흡기계 바이러스들의 계속적인 발견과 그 실험실진단법의 확립등을 들수 있다. 한편 백신개발에 대한 확립 등을 들수있다. 한편 백신개발에 대한 발자취를 보면 폴리오를 위시하여 홍역(Measles)백신, 멈프스(Mumps)및 풍진 (Rubella virus) 백신등의 개발은 근래 선,후진국을 막론하고 이러한 전염병의 예방효과가 눈에 띠게 덕을 보고있는 것이다. 지금 세계적으로 많은 전염병의 병원체가 바이러스라는 것이 알려져 있고 또한 이에 대한 백신의 개발연구가 활발하게 진행되고 있다. 이번 기회에 바이러스백신의 전망이라는 제목을 가지고 논하게 된것을 기쁘게 생가하며 동시에 어려운 과제라고도 생각된다. 왜냐하면 아직 우리나라에서는 생산을 못하고 있는것이 많은데 그 전망을 말하기가 어려운 까닭이며 또한 제한된 지면에서 충분히 고찰하기는 어렵다. 우리나라에서 자주 거론되는 백신 및 종류에 국한하여 그 문제점과 앞으로의 전망을 고찰해 보기로 한다.